Founded in 1978, CMA-Medina was until now in the hands of Straco, the investment vehicle of De Raedt and Verheyden. The lab group employs around 800 people and operates 8 labs in Flanders. Together with Biogroup founder and clinical biologist Stéphane Eimer, the business family will hold the majority of the shares in Biogroup.
Like CMA-Medina, the French group offers routine and specialized analyses for clinical biology across France: from its home base in the ‘Grand Est’ (Alsace and Burgundy) to Greater Paris, the southeast of France and Corsica. In France, Biogroup is already the largest player in a market with an annual turnover of EUR 6 billion. In 2018, the group achieved a turnover of EUR 600 million. By means of comparison: in Belgium, of which Flanders is the northern region, CMA-Medina is the main leader in a market worth over EUR 1 billion.